Researchers at Massachusetts Eye and Ear/Harvard Medical School and Boston University have successfully shown neuroprotection in a Parkinson’s mouse model using new techniques to deliver drugs across the naturally impenetrable blood-brain barrier. Their findings, published in Neurosurgery, lend hope to patients around the world with neurological conditions that are difficult to treat due to a barrier mechanism that prevents approximately 98 percent of drugs from reaching the brain and central nervous system.
“We are developing a platform that may eventually be used to deliver a variety of drugs to the brain,” said senior author Benjamin S. Bleier, M.D. (in photo), of the department of otolaryngology at Mass. Eye and Ear/Harvard Medical School. “Although we are currently looking at neurodegenerative disease, there is potential for the technology to be expanded to psychiatric diseases, chronic pain, seizure disorders and many other conditions affecting the brain and nervous system down the road.”
Using nasal mucosal grafting, researchers delivered glial derived neurotrophic factor (GDNF), a therapeutic protein in testing for treating Parkinson’s disease, to the brains of mice. They showed through behavioral and histological data capture that their delivery method was equivalent to direct injection of GDNF – the current gold standard for delivering this drug in Parkinson’s disease despite its traumatic nature and high complication rates – in diffusing drugs to the brain.
The researchers chose to test their delivery method with GDNF because the therapy has been shown to delay and even reverse disease progression of Parkinson’s disease in pre-clinical models. The study was funded by The Michael J. Fox Foundation for Parkinson’s Research (MJFF).
“Brain diseases are notoriously difficult to treat due to the natural protections the body builds against intrusion,” said Jamie Eberling, Ph.D., senior associate director of MJFF research programs. “Dr. Bleier’s group has identified a potential avenue to pass that barrier, and we look forward to the next stage of research to further test its utility in people with Parkinson’s disease .”
Nasal mucosal grafting is a technique regularly used in the ENT field to reconstruct the barrier around the brain after surgery to the skull base. ENT surgeons commonly use endoscopic approaches to remove brain tumors through the nose by making a window through the blood-brain barrier to access the brain. Once they have finished the treatment, they use adjacent nasal lining to rebuild the hole in a permanent and safe way. The safety and efficacy of these methods have been well established through long-term clinical outcomes studies in the field, with the nasal lining protecting the brain from infection just as the blood brain barrier has done.
Dr. Bleier saw an opportunity to apply these techniques to the widespread clinical dilemma of delivering drugs across the barrier to the brain and central nervous system. By functionally replacing a section of the blood-brain barrier with nasal mucosa, which is more than 1,000 times more permeable than the native barrier, surgeons may create a “screen door” to allow for drug delivery to the brain and central nervous system.
The technique has the potential to benefit a large population of patients with neurodegenerative disorders, where there remains a specific unmet need for blood-brain penetrating therapeutic delivery strategies.
“We see this expanding beyond Parkinson’s disease, as there are multiple diseases of the brain that do not have good therapeutic options,” Dr. Bleier said. “It is a platform that opens doors for new discovery and could enable drug development for an underserved population.”
The Latest on: neurodegenerative disorders
via Google News
The Latest on: neurodegenerative disorders
- Prothena Announces Promising New Preclinical and Clinical Data from its Neurodegenerative Programs Selected for Oral Presentations at AD/PD 2021on February 24, 2021 at 6:59 pm
Robust preclinical data support the benefit of PRX005, a novel anti-tau antibody, for the potential treatment Alzheimer's disease New ...
- How a boxing class is helping those with Parkinson’s Diseaseon February 24, 2021 at 5:29 pm
When it comes to the disease, many people are familiar with the tremors, but it’s not just tremors. Parkinson’s affects the whole body and Rock Steady Boxing can help out with that.
- Long runs of homozygosity are associated with Alzheimer’s diseaseon February 24, 2021 at 8:02 am
Long runs of homozygosity (ROH) are contiguous stretches of homozygous genotypes, which are a footprint of inbreeding and recessive inheritance. The presence of recessive loci is suggested for ...
- Alzheon CEO Presents Overview of Oral Anti-Amyloid ALZ-801 Phase 3 Program at 9 th Neurodegenerative Drug Development Summiton February 24, 2021 at 8:00 am
Alzheon, Inc., a clinical-stage biopharmaceutical company focused on developing new medicines for patients suffering from Alzheimer’s disease (AD) and ...
- Study offers new insights into "Niemann-Pick type C disease"on February 24, 2021 at 5:27 am
In the journal Nature Communications, scientists of the German Center for Neurodegenerative Diseases (DZNE) report new findings on the mechanisms of "Niemann-Pick type C disease" (NPC).
- 'Fat jam' in the cell: New insights into the brain disease Niemann-Pick type Con February 24, 2021 at 4:54 am
In the journal Nature Communications, scientists of the German Center for Neurodegenerative Diseases (DZNE) report new findings on the mechanisms of Niemann-Pick type C disease (NPC). This rare brain ...
- Global Rare Neurodegenerative Disease Treatment Market (2020 to 2030) - Major Drivers, Restraints, and Opportunities - ResearchAndMarkets.comon February 24, 2021 at 3:05 am
The "Rare Neurodegenerative Disease Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020-2030" report has been added to ResearchAndMarkets.com's offering.
- New platform can help treat neurodegenerative diseases through regenerative medicineon February 23, 2021 at 9:03 pm
Imagine if surgeons could transplant healthy neurons into patients living with neurodegenerative diseases or brain and spinal cord injuries. And imagine if they could "grow" these neurons in the ...
- Holtzman, Karch honored for research into neurodegenerative diseaseson February 23, 2021 at 10:23 am
Holtzman received the Rainwater Annual Prize for Outstanding Innovation in Neurodegenerative Research, and Karch was awarded the Rainwater Prize for Innovative Early-Career Scientists. Holtzman and ...
- Prion diseases: New clues in the structure of prion proteinson February 22, 2021 at 4:54 am
Prion diseases are a group of rapidly progressive, fatal and infectious neurodegenerative disorders affecting both humans and animals. Bovine spongiform encephalopathy (BSE) or "mad cow" disease is ...
via Bing News